TABLE 4.
Clinical features in control and intervention groups at baseline and post-intervention.
| Outcomes | Control group (n = 24)1 | Intervention group (n = 22)1 | ||||||
|
|
|
|||||||
| Baseline mean (±SD) median (P25;P75) | Post-intervention mean (±SD) median (P25;P75) | Post-intervention− baseline difference Δ mean (±SD) Δ median (P25; P75) | Within-group analysis p-value | Baseline mean (±SD) median (P25;P75) | Post-intervention mean (±SD) median (P25;P75) | Post-intervention− baseline difference Δ mean (±SD) Δ median (P25; P75) | Within-group analysis p-value | |
| FIQR (Range: 0−100) | 60.2 (±10.5) 60.5 (52.5; 68.9) | 57.6 (±15.6) 61.2 (50.4; 68.4) | −2.2 (±16.1) −0.05 (9.1; 7.6) | 0.515b | 59.3 (±9.2) 58.3 (53.3; 67.1) | 39.5 (±21.8) 40.1 (23.8; 58.8) | −19.9 (±18.8) −15.8 (−34.2; −3.1) | p < 0.001b |
| VAS (Range: 0−10) | 7.6 (±1.6) 8.0 (7.0; 8.8) | 7.6 (±1.9) 8.0 (7.0; 9.0) | −0.04 (±2.1) 0.0 (−1.0; 1.0) | 0.935a | 7.7 (±1.4) 8.0 (7.0; 9.0) | 5.4 (±2.3) 6.0 (3.8; 7.3) | −2.3 (±2.5) −2.5 (−4.3; −0.8) | 0.001a |
| VAS GI (Range: 0−10) | 3.1 (±1.4) 3.0 (1.9; 4.7) | 2.3 (±1.3) 2.2 (1.5; 2.6) | −0.9 (±1.3) −0.5 (−1.7; 1.7) | 0.007a | 3.4 (±1.5) 3.4 (2.2; 4.4) | 1.4 (±1.3) 1.2 (0.1; 2.6) | −2.0 (±0.9) −2.1 (−2.7; −1.3) | p < 0.001a |
| BPI (Range: 0−20) | 14.1 (±2.2) 14.4 (12.9; 15.2) | 13.0 (±3.6) 13.4 (11.1; 15.5) | −1.1 (±2.7) −1.0 (−2.4; 1.1) | 0.062b | 12.5 (±2.3) 12.8 (10.8; 14.1) | 8.7 (±4.7) 10.2 (4.4; 12.2) | −3.8 (±4.1) −3.2 (−5.7; −0.7) | p < 0.001b |
| PSQI (Range: 0−21) | 15.1 (±4.0) 16.0 (12.0; 18.0) | 13.9 (±4.5) 14.5 (11.0; 17.0) | −1.2 (±2.6) −1.0 (−2.8; 0.8) | 0.037b | 15.0 (±5.2) 15.0 (10.8; 19.5) | 11.6 (±5.7) 9.5 (8.5; 16.3) | −3.5 (±4.6) −3.0 (−8.0; 0.8) | 0.002b |
| FSS (Range: 0−7) | 6.4 (±0.7) 7.0 (6.0; 7.0) | 5.9 (±1.2) 6.0 (5.0; 7.0) | −0.5 (±1.0) 0.0 (−1.0; 0.0) | 0.038a | 5.5 (±1.1) 6.0 (4.8; 6.0) | 4.4 (±1.7) 5.0 (3.8; 5.3) | −1.1 (±1.2) −1.0 (−2.0; 0.0) | 0.001a |
| SF36 (Range: 0−100) | 38.6 (±7.2) 38.9 (33.1; 42.7) | 42.2 (±9.7) 42.2 (36.5; 47.2) | 3.6 (±10.4) 2.2 (−4.9; 11.9) | 0.137a | 44.0 (±10.3) 42.6 (36.9; 53.5) | 54.3 (±12.3) 58.4 (43.5; 63.6) | 10.2 (±11.2) 9.0 (3.4; 15.9) | p < 0.001a |
| SF36 Physical Component (Range: 0−100) | 30.9 (±8.2) 31.8 (22.6; 35.6) | 34.8 (±14.3) 30.9 (21.7; 49.6) | 3.9 (±13.5) 1.3 (−4.8; 13.6) | 0.168b | 33.4 (±11.4) 34.6 (25.0; 41.0) | 51.5 (±18.8) 56.3 (36.5; 66.7) | 18.1 (±20.0) 22.5 (−1.0; 36.0) | p < 0.001b |
| SF36 Mental Component (Range: 0−100) | 38.6 (±15.8) 36.2 (26.2; 48.7) | 47.2 (±19.8) 43.3 (28.9; 64.1) | 8.5 (±23.1) 7.1 (−2.6; 24.7) | 0.052a | 54.4 (±23.1) 56.3 (33.7; 71.4) | 63.4 (±21.4) 68.5 (51.3; 78.8) | 8.9 (±21.0) 8.1 (1.9; 19.2) | 0.023a |
1Female participants.
FIQR, Revised Fibromyalgia Impact Questionnaire; VAS, Visual Analog Pain Scale; VAS GI, Visual Analog Scale from gastrointestinal symptoms; BPI, Brief Pain Inventory; PSQI, Pittsburg Sleep Quality Index; FSS, Fatigue Severity Survey; SF36, Short Form 36.
ap-value calculated by Wilcoxon Test between baseline and post-intervention, within-groups mean values;
bp-value calculated by Paired Samples t-test between baseline and post-intervention, within-groups mean values.